The Fate of Non-Scalp Hair in Alopecia Areata Universalis Under Baricitinib Treatment: A Real-World Single-Center Experience

This study evaluated the effectiveness of baricitinib in treating alopecia areata universalis (AAU) in nonscalp areas, involving 15 patients over 28 to 72 weeks. Results showed that 80% of patients experienced scalp hair regrowth within 12 weeks, with eyebrow regrowth in 93%, eyelash regrowth in 80%, pubic hair regrowth in 73%, and axillary hair regrowth in 47%. The study confirmed baricitinib's efficacy in promoting hair regrowth in both scalp and nonscalp areas, though the timing varied. Pubic hair regrowth was more frequent than axillary hair regrowth, which was the most resistant. Further research with larger cohorts and longer follow-up is recommended.